Bevacizumab compared with dexamethasone for brain damage after radiation treatment
Compares bevacizumab with dexamethasone for radiation necrosis after treatment for glioma or brain metastases.
Key facts
- Who runs it
- Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
- Where
- Netherlands7 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Bevacizumab for the treatment of cerebral RAdiation Induced NecrosiS (BRAINS) study: A multicenter, open-label, randomized clinical trial to assess the clinical efficacy and cost-effectiveness of bevacizumab versus corticosteroids as first-line treatment in patients with symptomatic cerebral radiation necrosis after radiation for high grade glioma or brain metastases
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 408 people, planned
- Started
- 10 Jul 2025
- Expected to end
- 1 May 2029
- Type of study
- Interventional
- Record updated
- 6 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with high grade glioma or brain metastases who have symptoms from brain tissue damage caused by radiation (radiation necrosis). It compares bevacizumab with dexamethasone as the first treatment.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- A new episode of symptomatic radiation necrosis after focal (re-)irradiation, confirmed by the local neuro-oncology board. KPS score ≤ 90, plus loss of at least one point on the NANO scale or a lasting headache from the necrosis. Glioma: high-grade diffuse glioma by WHO 2021 criteria (grade 3-4). Brain metastases: from a solid tumor, at least 3 months after radiation, with no sign of tumor growth.
- Earlier treatment
- Must have had focal radiation or re-radiation to the brain. No bevacizumab in the 3 months before randomization. Limits on earlier dexamethasone: on average ≤1.5 mg/day in the 4 weeks before the last 4 weeks; higher doses are allowed in the last 4 weeks. No high-dose dexamethasone (≥ 4 mg/day for ≥ 3 weeks) for this lesion in the 6 months before, apart from the last 8 weeks.
- Biomarker or test result
- For glioma: confirmed tissue diagnosis, for example astrocytoma IDH-mutant or IDH-wildtype, oligodendroglioma with 1p/19q codeletion, or glioblastoma IDH-wildtype.
Main reasons for not taking part
- Life expectancy under 3 months
- Signs of brain swelling that need urgent surgery
- Allergy to bevacizumab or dexamethasone, or poor kidney function (creatinine clearance <30 mL/min)
- Serious heart or blood vessel disease, bleeding history or high bleeding risk
- Pregnancy or breastfeeding
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Age ≥ 18 years old
- Only for HGG patients: No minimum time interval between diagnosis of pseudoprogression/sCRN and completion of focal (re-) irradiation
- Only for HGG patients: A working diagnosis of pseudoprogression/CRN is required
- Episode of sCRN after completion of focal (re-)irradiation, as determined by the local Multidisciplinary Neuro-Oncology Board. Patients with a previously treated sCRN lesion may be included provided that they develop a new, distinct episode of sCRN
- KPS score ≤ 90 and either (a) a minimum loss of one point on the Neurologic Assessment in Neuro-Oncology (NANO) scale as compared to the maximum score of 23 points due to sCRN, or (b) a persisting headache attributable to sCRN
- Able to understand the patient information, online tests and questionnaires
- Written informed consent
- Only for BM patients: BM of solid tumor, including all primary tumor types
- Only for HGG patients: A confirmed histological diagnosis of high-grade diffuse glioma according to WHO 2021 criteria, including: astrocytoma, IDH-mutant, grade 3-4; astrocytoma, IDH-wildtype (sybtype molecular glioblastoma); oligodendroglioma, 1p/19q codeleted, grade 3; diffuse glioma, NEC, grade 3-4; or glioblastoma, IDH-wildtype, grade 4
- Only for BM patients: Time interval of ≥ 3 months between diagnosis of sCRN and completion of focal (re-)irradiation
- Only for BM patients: A working diagnosis of CRN without evidence of a combination with tumor progression is required
Who cannot take part
- Dexamethasone use prior to randomization o In 4 weeks prior to the 4 weeks of permitted higher (>1.5 mg/day) dosing of dexamethasone: average daily dose of dexamethasone (or an equivalent dose of an alternative corticosteroid) ≤1.5 mg/day over this 4-week period. o 4 weeks directly prior to randomization: higher average daily doses of dexamethasone (or an equivalent dose of an alternative corticosteroid)(> 1.5 mg/day) is permitted
- Impending radiological or clinical signs of brain herniation necessitating immediate decompressive surgery
- Prior treatment with bevacizumab <3 months before randomization
- Previous treatment with high-dose dexamethasone (≥ 4 mg/day for ≥ 3 weeks) for the sCRN lesion within the 6 months prior to randomization, excluding the 8 weeks immediately preceding randomization, is not permitted
- Any comorbidity or condition that prevents safe administration of the studied medication, determined by the treating physician, including but not limited to: a. Intolerance for murine proteins b. Hypersensitivity or allergy to the active substance or to any of the excipients of bevacizumab or dexamethasone c. Nephrotic syndrome or abnormal renal function o Calculated (Cockcroft-Gault) or measured creatinine clearance <30 mL/min; proteinuria will be evaluated according to local protocol. Patients exceeding the locally defined threshold at baseline should undergo 24 hours urine collection and must demonstrate ≤ 1 g of protein/24 hr. d. Clinical significant cardiovascular disease o Uncontrolled hypertension (systolic BP >150mmHg and/or diastolic >100mmHg) despite the use of ≥ 3 antihypertensive drugs o Previous hypertensive crisis, hypertensive encephalopathy or previous reversible posterior leukoencephalopathy syndrome (RPLS) o Non-tumor-related vascular events: cerebral or cardiac ischemia or peripheral artery disease < 3 months before randomization Deep venous thrombosis, lung embolism < 6 weeks before randomization. Patients are allowed if deep venous thrombosis, lung embolism occurs > 6 weeks before randomization and are adequately treated with anticoagulants. o History of aortic aneurysm or dissection o Congestive heart failure NYHA II-IV e. History of gastro-intestinal fistula, perforation or abscess < 6 months f. History of bleeding g. Excess risk of bleeding i. High-dose radiotherapy to the mediastinum, abdomen, or lower pelvis; administration of bevacizumab should only be considered after prior consultation with a pulmonologist or oncologist j. Pregnancy or lactation. Women of child bearing potential (WOCBP) must have a negative serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 7 days prior to randomization. WOCBP and female partners of male patients must comply with adequate contraception methods as requested by the study protocol k. Evidence of any other medical conditions (such as psychiatric illness, physical examination or laboratory findings) that may interfere with the study treatment, affect patient compliance or place the patient at high risk for treatment-related complications according to the treating physician l. Current or recent (within 30 days of first study treatment) treatment with another investigational drug
- Life expectancy <3 months
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To compare the clinical efficacy of first-line bevacizumab vs dexamethasone for cerabral radiation necrosis (sCRN) in high grade glioma (HGG) and brain metastases (BM) patients
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Bevacizumab for the treatment of cerebral RAdiation Induced NecrosiS (BRAINS) study: A multicenter, open-label, randomized clinical trial to assess the clinical efficacy and cost-effectiveness of bevacizumab versus corticosteroids as first-line treatment in patients with symptomatic cerebral radiation necrosis after radiation for high grade glioma or brain metastases
- Plain-language title
- Bevacizumab compared with dexamethasone for brain damage after radiation treatmentGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 6 November 2026